Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical cancer (COMPASSION-13): a phase 2 study

CONCLUSIONS: Cadonilimab combined with standard therapy was acceptable, with encouraging antitumor activity in patients with R/M CC.PMID:38372727 | DOI:10.1158/1078-0432.CCR-23-3162

Source: Clinical Cancer Research - February 19, 2024 Category: Cancer & Oncology Authors: Hanmei Lou Hongbing Cai Xin Huang Guiling Li Li Wang Fei Liu Wenjing Qin Ting Liu Wei Liu Zhongmin Maxwell Wang Baiyong Li Yu Xia Jing Wang Source Type: research